Inventiva (IVA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Inventiva, a clinical-stage biopharmaceutical company, has reported its total voting rights and shares forming its capital as of November 4, 2024. The company is actively advancing its lead product candidate, lanifibranor, in a Phase 3 clinical trial for MASH/NASH treatment and holds a robust pipeline with additional drug candidates. As a public company listed on Euronext Paris and Nasdaq, Inventiva continues to explore further development opportunities in its field.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia Stock Could Take a Beating from Supply Snags on Blackwell Chips
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
